SEC Form SC TO-T filed by Sage Therapeutics Inc.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
of the Securities Exchange Act of 1934
A Wholly Owned Subsidiary of
Senior Vice President and Chief Financial Officer
Supernus Pharmaceuticals, Inc.
9715 Key West Ave
Rockville, Maryland 20850
Telephone: (301) 838-2500
Mark I. Gruhin, Esq.
George A. Naya, Esq.
Saul Ewing LLP
1919 Pennsylvania Avenue NW, Suite 550
Washington, DC 20006
Telephone: (202) 333-8800
|
Exhibit No.
|
| |
Description
|
|
|
(a)(1)(A)
|
| | | |
|
(a)(1)(B)
|
| | | |
|
(a)(1)(C)
|
| | | |
|
(a)(1)(D)
|
| | | |
|
(a)(1)(E)
|
| | Summary Advertisement, published in the New York Times on July 2, 2025.* | |
|
(a)(5)(A)
|
| | | |
|
(a)(5)(B)
|
| | | |
|
(b)
|
| | Not applicable. | |
|
(d)(1)
|
| | Agreement and Plan of Merger, dated June 13, 2025, by and among Supernus Pharmaceuticals, Inc., Saphire, Inc. and Sage Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Supernus Pharmaceuticals, Inc. on June 16, 2025 (File No. 001-36544)). | |
|
(d)(2)
|
| | | |
|
(d)(3)
|
| | | |
|
(d)(4)
|
| | | |
|
(g)
|
| | Not applicable. | |
|
(h)
|
| | Not applicable. | |
|
107
|
| | |
| | | | Saphire, Inc. | | ||||||
| Date: July 2, 2025 | | |
By:
/s/ Jack A. Khattar
|
| ||||||
| | | | | | |
Name:
Jack A. Khattar
|
| |||
| | | | | | |
Title:
President and Treasurer
|
| |||
| | | | Supernus Pharmaceuticals, Inc. | | ||||||
| | | |
By:
/s/ Timothy C. Dec
|
| ||||||
| | | | | | |
Name:
Timothy C. Dec
|
| |||
| | | | | | |
Title:
Senior Vice President and
Chief Financial Officer
|
|